Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a report on Monday.

Vanda Pharmaceuticals Trading Down 0.4 %

NASDAQ:VNDA opened at $4.81 on Friday. The company has a 50-day moving average of $4.86 and a 200-day moving average of $5.20. The firm has a market cap of $280.46 million, a price-to-earnings ratio of -17.18 and a beta of 0.76. Vanda Pharmaceuticals has a twelve month low of $3.46 and a twelve month high of $6.75.

Insider Transactions at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the transaction, the director now directly owns 44,857 shares in the company, valued at approximately $231,910.69. This trade represents a 10.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 8.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in VNDA. Bank of New York Mellon Corp grew its position in Vanda Pharmaceuticals by 8.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 257,995 shares of the biopharmaceutical company’s stock worth $1,458,000 after purchasing an additional 20,721 shares during the last quarter. Panagora Asset Management Inc. lifted its stake in shares of Vanda Pharmaceuticals by 4.3% in the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 2,509 shares during the period. Monaco Asset Management SAM acquired a new stake in Vanda Pharmaceuticals during the second quarter worth about $1,090,000. American Century Companies Inc. increased its stake in Vanda Pharmaceuticals by 7.5% during the second quarter. American Century Companies Inc. now owns 269,971 shares of the biopharmaceutical company’s stock valued at $1,525,000 after acquiring an additional 18,733 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at approximately $39,000. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.